Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Appoints Johnny Mikell as Global Head of Quality

Mumbai, October 03, 2019: Pharma major Lupin Limited (Lupin) announced the appointment of Johnny Mikell as President and Global Head of Quality. Johnny will be based out of Lupin's US offices and will lead the Company's Quality function globally; he will help steer the company towards enhanced standards of Quality and Compliance.

Johnny is a very competent Quality leader and brings to Lupin over 35 years of rich pharmaceutical industry experience and expertise. He has significant experience in global quality operations and compliance in the generics, branded and API segments. In his most recent engagement, Johnny was the Global Head of Quality and Compliance at Apotex. Prior to that, he served as the Global Head of Quality and Compliance at Amneal. Johnny has also held leadership positions at UCB, Novartis and Bausch & Lomb.

Johnny holds a Bachelor of Science degree in Biology and Master of Science in Microbiology. He has attained his academic qualifications from leading institutions like Duke University, London's British Standards Institute and Harvard.

Commenting on Johnny's appointment, **Nilesh Gupta, Managing Directo**r, Lupin said, "Lupin is committed to raising the bar to become the global benchmark for Quality and Compliance. We are delighted to have Johnny join our leadership team. We have a strong Quality and Compliance team and having Johnny at the helm will help us achieve our near-term goal of ensuring that our sites are compliant and long-term goal of being the best when it comes to Quality and Compliance".

About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31st March 2019, Lupin's Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Arvind Bothra
Head – Investor Relations and M&A / Corporate Communications
Email: arvindbothra@lupin.com
Ph: +91-22-66408237